Immunogenicity of a bivalent killed thimerosal-free oral cholera vaccine, Euvichol, in an animal model

이은영; 이세나; 노세미; 김재욱; 최석근; 이영진; 박주영; 송만기; 양재승

추천

검색

자료유형: 학술저널

저자정보: 이은영 (국제백신연구소(IVI)) 이세나 (국제백신연구소(IVI)) 노세미 (국제백신연구소(IVI)) 김재욱 (국제백신연구소(IVI)) 최석근 (㈜유바이오로직스) 이영진 (㈜유바이오로직스) 박주영 (㈜유바이오로직스) 송만기 (국제백신연구소(IVI)) 양재승 (국제백신연구소(IVI))

저널정보: 대한백신학회 Clinical and Experimental Vaccine Research Clinical and Experimental Vaccine Research Vol.7 No.2

발행연도: 2018.1

수록면: 104 - 110 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: An oral cholera vaccine (OCV), Euvichol, with thimerosal (TM) as preservative, was prequalified by the World Health Organization (WHO) in 2015. In recent years, public health services and regulatory bodies recommended to eliminate TM in vaccines due to theoretical safety concerns. In this study, we examined whether TM-free Euvichol induces comparable immunogenicity to its TM-containing formulation in animal model. Materials and Methods: To evaluate and compare the immunogenicity of the two variations of OCV, mice were immunized with TM-free or TM-containing Euvichol twice at 2-week interval by intranasal or oral route. One week after the last immunization, mice were challenged with Vibrio cholerae O1 and daily monitored to examine the protective immunity against cholera infection. In addition, serum samples were obtained from mice to measure vibriocidal activity and vaccine-specific IgG, IgM, and IgA antibodies using vibriocidal assay and enzyme-linked immunosorbent assay, respectively. Results: No significant difference in immunogenicity, including vibriocidal activity and vaccine-specific IgG, IgM, and IgA in serum, was observed between mice groups administered with TM-free and -containing Euvichol, regardless of immunization route. However, intranasally immunized mice elicited higher levels of serum antibodies than those immunized via oral route. Moreover, intranasal immunization completely protected mice against V. cholerae challenge but not oral immunization. There was no significant difference in protection between two Euvichol variations. Conclusion: These results suggested that TM-free Euvichol could provide comparable immunogenicity to the WHO prequalified Euvichol containing TM as it was later confirmed in a clinical study. The pulmonary mouse cholera model can be considered useful to examine in vivo the potency of OCVs.

참고문헌 (27)

참고문헌 신청

Ali M / 2015 / Updated global burden of cholera in endemic countries / PLoS Negl Trop Dis 9:e0003832

Clemens JD / 2017 / Cholera / Lancet 390:1539~1549

Deen J / 2016 / The scenario approach for countries considering the addition of oral cholera vaccination in cholera preparedness and control plans / Lancet Infect Dis 16:125~129

Baker JP / 2008 / Mercury, vaccines, and autism: one controversy, three histories / Am J Public Health 98:244~253

Geier MR / 2003 / Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication / Exp Biol Med (Maywood) 228:660~664

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!